alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Home › Research › Topics › large-phase

large-phase

7 studies tagged large-phase, dated 2011-07-01 to 2026-09-01. Bibliography: BibTeX (.bib) · RIS (.ris)

Newest in this topic

  1. Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes 2026-09-01
  2. Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal 2026-08-01
  3. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab 2021-01-01

Studies

7 studies carry this tag.

Date range

2011 to 2026

Top journals

  • Alzheimer's & dementia : the journal of the Alzheimer's Association 2
  • Journal of Alzheimer's disease : JAD 2
  • Alzheimer's research & therapy 1
  • Drugs 1
  • The journal of prevention of Alzheimer's disease 1

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

  1. Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes

    ✓ Peer-reviewed alzhub usefulness score 86 out of 100. Drugs 2026-09-01 Treatments

    A recent Phase 3 trial did not meet its primary clinical endpoint in the overall population, but demonstrated significant benefits in cognition, function, and brain volumetric MRI (vMRI) in the prespecified subgroup with mild cognitive impairment (MCI).

  2. Volume change with gantenerumab: Impact of amyloid-related imaging abnormalities and amyloid removal

    ✓ Peer-reviewed alzhub usefulness score 75 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2026-08-01 Treatments

    ARIA are not associated with long-term parenchymal reduction; rather, they are linked to a fluid shift from the external space to the ventricles.

  3. Thirty-Six-Month Amyloid Positron Emission Tomography Results Show Continued Reduction in Amyloid Burden with Subcutaneous Gantenerumab

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. The journal of prevention of Alzheimer's disease 2021-01-01 Treatments

    Previous findings from the positron emission tomography (PET) substudy of the SCarlet RoAD and Marguerite RoAD open-label extension (OLE) showed gantenerumab doses up to 1200 mg every 4 weeks administered subcutaneously resulted in robust beta-amyloid (Aβ) plaque removal over 24 months in people with prodromal-to-moderate Alzheimer's disease (AD).

  4. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials

    ✓ Peer-reviewed alzhub usefulness score 80 out of 100. Alzheimer's research & therapy 2016-05-12 Tau biomarkers

    These phase 3 global trials confirmed lack of efficacy of bapineuzumab at tested doses on clinical endpoints in patients with mild to moderate AD.

  5. Changes in Brain Volume with Bapineuzumab in Mild to Moderate Alzheimer's Disease

    ✓ Peer-reviewed alzhub usefulness score 67 out of 100. Journal of Alzheimer's disease : JAD 2016-01-01 Treatments

    Bapineuzumab produced an increase in ventricular volume compared with placebo.

  6. Cognitive and functional decline and their relationship in patients with mild Alzheimer's dementia

    ✓ Peer-reviewed alzhub usefulness score 74 out of 100. Journal of Alzheimer's disease : JAD 2015-01-01 Treatments

    The cognitive treatment effect appeared to explain the majority of the functional treatment effect.

  7. Prevalence of asymptomatic vasogenic edema in pretreatment Alzheimer's disease study cohorts from phase 3 trials of semagacestat and solanezumab

    ✓ Peer-reviewed alzhub usefulness score 77 out of 100. Alzheimer's & dementia : the journal of the Alzheimer's Association 2011-07-01 Treatments

    VE seems to be rare at baseline in patients with AD in clinical trials, 2 of 2,762 associated with AD.

All topic tags with their study counts